Delivery Order SPE2DB20D2014-SPE2DB25FC76A
- Not listed
- The Defense Logistics Agency awarded a $35,153.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL syringes. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This contract is a child order under the company's...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. The contract is firm fixed price with an ultimate completion date of August 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL syringes, a biologic medication used to treat moderate-to-severe eosinophilic asthma. This firm fixed-price delivery order, issued on July 31, 2025, represents a non-set-aside competitive award and is scheduled for completion by August 21, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on August 7, 2025, with a completion date of August 28, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty pharmaceutical product used for treating severe asthma and eosinophilic...
- The Defense Logistics Agency (DLA) awarded a $9,374.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 mL syringes. The award, issued on August 14, 2025, is scheduled for completion by September 5, 2025, with performance to be completed at the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside, competitively awarded procurement and is issued as a child contract under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on August 11, 2025, with completion targeted for September 2, 2025. This is a non-set-aside, competitively awarded contract under which AmerisourceBergen will deliver the specified pharmaceutical product to support federal medical supply needs. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is not set aside for any socioeconomic category and is scheduled for completion by August 12, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC76ADelivery Order
The Defense Logistics Agency awarded a $23,435.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on August 15, 2025, with an ultimate completion date of September 8, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to the company's distribution center in Conshohocken, Pennsylvania, supporting military and federal healthcare supply chains. Tezspire is a biologic medication approved for moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps treatment, reflecting the breadth of specialty pharmaceutical products AmerisourceBergen supplies through its DLA prime vendor contract. As a major pharmaceutical distributor, AmerisourceBergen maintains extensive federal procurement capability across brand-name and generic medications, biologics, vaccines, and medical supplies, positioning it as a critical vendor for Defense Health Agency and other federal healthcare systems. The company's competitively awarded contracts and demonstrated logistics infrastructure support DLA's strategic medical supply chain operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.4k | 8/15/25 |